No Data
The tenth batch of national procurement reporting documents have been leaked, industry insiders: does not represent the final list of centralized procurement varieties. The competition intensity will reach new heights.
①A document of the tenth batch of national procurement reporting catalog has circulated within the industry. Today, when the reporter verified with the relevant department, they indicated that it is an internal document not for public release, and the formal joint procurement document will be released publicly later. ②Several industry experts have provided feedback to the reporter, stating that this reporting catalog does not represent the final procurement catalog. However, the competitive landscape of the tenth batch of national procurement will involve at least seven companies. ③The competition for the tenth batch of national procurement will be exceptionally fierce.
Sino Biopharm (01177.HK): Zentech Sun considered purchasing shares under the stock incentive plan.
Glory announced on October 9 that sino biopharmaceuticals (01177.HK) announced the implementation of a share incentive plan for its subsidiary Zhongda Tianqing Pharmaceutical Group Co., Ltd. ("Zhongda Tianqing") on May 7, 2024. From October 8, 2024, to October 9, 2024, the trustee repurchased a total of 21 million shares of the company in the market according to the terms and conditions of the share incentive plan, to be used for subsequent implementation of share incentives for selected participants. The average cost per share is approximately HK$3.81.
Sino Biopharm Unit Obtains China License for YZY Bio's Cancer Drug
sino biopharm's subsidiary signs exclusive licensing and cooperation agreement with Uzziel Biopharma.
Sino Biopharm (01177) announced that its subsidiary, China Grand Pharmaceutical Group Co., Ltd. ("China Grand Pharmaceutical"), has signed an exclusive license and cooperation agreement with Wuhan Youzhiyou Biopharmaceutical Co., Ltd. ("Youzhiyou Biopharm") for the development, registration, production, and commercialization of M701 developed by Youzhiyou Biopharm in the mainland China region. China Grand Pharmaceutical will make an upfront payment and R&D milestone payments to Youzhiyou Biopharm of approximately 0.315 billion RMB based on the progress of research and development, and will pay up to a maximum of 0.7 billion RMB.
sino biopharm (01177.HK): Signed an exclusive licensing and cooperation agreement with Uchengbio.
Grain Alliance reported on October 8th that sino biopharm (01177.HK) announced that its subsidiary, Nanjing Pharmaceutical Group Co., Ltd. ("Nanjing Pharmaceutical"), has signed an exclusive license and cooperation agreement with wuhan Youzhiyao Biopharmaceutical Co., Ltd. ("Youzhiyao Biopharm") in mainland China. Nanjing Pharmaceutical will have exclusive and separable licenses for the research, development, registration, production, and commercialization of M701 developed by Youzhiyao Biopharm in China. Nanjing Pharmaceutical will make an initial payment of approximately 0.315 billion RMB to Youzhiyao Biopharm for the licensing product, based on the progress of research and development.
Express News | Sino Biopharmaceutical - Unit Will Pay Approximately RMB315 Mln as Upfront Payment
No Data
No Data
